A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-10-16) →
What happened
Samsung Biologics disclosed a subsidiary's acquisition of PolyPeptide Group AG, worth US$1.98B.
For context, this deal is worth about 24.5% of the company's consolidated total assets.
| Target | PolyPeptide Group AG |
|---|---|
| Deal value | US$1.98B |
| vs. company assets | 24.5% |
| Filed | 2026-08-31, Decision to acquire shares/equity in another company (subsidiary) |
| Source | DART rcept 20260831800556 → open original filing |
Versions of this filing
- 2026-08-31Original (this page)
- 2026-10-16Amendment 1
Source: DART. Information only, not investment advice.